{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:18:49Z","timestamp":1740136729493,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Determine the COVID-19 seroconversion rate for patients with multiple myeloma receiving a COVID-19 vaccine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>After 45 patients received their second COVID-19 vaccine dose, their serum IgG antibodies were measured: 22 with monoclonal gammopathy (MG) of unknown significance, 3 with smoldering myeloma, 2 with light chain amyloidosis, and 18 with MG (9 in remission, 6 out of remission, and 3 with free light-chain gammopathy alone). A second serum specimen was retained for 16 patients with MG. Their antibody levels were compared to those of 78 uninfected healthy vaccinated control patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three patients with MG had low antibody levels on blood collected 98, 100, and 113 days after the initial vaccine dose (2 with MG of unknown significance and 1 with hypogammaglobulemia). The other 40 patients with MG (seroconversion rate 93%) and both patients with amyloidosis produced antibodies. Relative to days after vaccination, patients with MG had lower antibody levels than control patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After receiving a COVID-19 vaccine, most patients with MG produce anti-SARS-CoV-2 antibodies comparable to levels in uninfected vaccinated healthy control patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmab113","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T20:14:25Z","timestamp":1637007265000},"page":"314-319","source":"Crossref","is-referenced-by-count":6,"title":["Adequate Antibody Response to COVID-19 Vaccine in Patients with Monoclonal Gammopathies and Light Chain Amyloidosis"],"prefix":"10.1093","volume":"53","author":[{"given":"Alan H B","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University of California , San Francisco, California , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ching","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of California , San Francisco, California , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Mei","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California , San Francisco, California , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-0401","authenticated-orcid":false,"given":"Kara L","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California , San Francisco, California , US"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"2","key":"2023020400340962300_CIT0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman","year":"2019","journal-title":"Acta Haematol."},{"issue":"26","key":"2023020400340962300_CIT0002","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2023020400340962300_CIT0003","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/HS9.0000000000000547","article-title":"SARS-CoV-2 vaccines in patients with multiple myeloma","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Hemasphere."},{"key":"2023020400340962300_CIT0004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial","volume":"17(5)","author":"Branagan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2023020400340962300_CIT0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cid\/ciaa979","article-title":"Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity","volume":"72(2)","author":"Lynch","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2023020400340962300_CIT0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-010-0047-9","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"5","author":"Kyle","year":"2010","journal-title":"Curr Hematol Malig Rep."},{"issue":"6","key":"2023020400340962300_CIT0007","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica."},{"issue":"20","key":"2023020400340962300_CIT0008","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2023020400340962300_CIT0009","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica."},{"issue":"1","key":"2023020400340962300_CIT0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia."},{"issue":"6","key":"2023020400340962300_CIT0011","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol."},{"key":"2023020400340962300_CIT0012","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14(1):81","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol."},{"issue":"8","key":"2023020400340962300_CIT0013","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell."},{"issue":"26","key":"2023020400340962300_CIT0014","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood."},{"issue":"7","key":"2023020400340962300_CIT0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2017.1322578","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"17","author":"Touzeau","year":"2017","journal-title":"Expert Opin Biol Ther."},{"key":"2023020400340962300_CIT0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2023020400340962300_CIT0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N Engl J Med."},{"key":"2023020400340962300_CIT0018","article-title":"Rate","author":"Wu","year":": 10.1093\/\/137","journal-title":"J Appl Lab Med."},{"key":"2023020400340962300_CIT0019","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","author":"Boyarsky","year":"2021;325(21):2204\u20132206","journal-title":"JAMA"},{"key":"2023020400340962300_CIT0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185(3)","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/3\/314\/49088034\/lmab113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/3\/314\/49088034\/lmab113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:34:53Z","timestamp":1675470893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/53\/3\/314\/6506530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,1,13]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmab113","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"type":"print","value":"0007-5027"},{"type":"electronic","value":"1943-7730"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,1,13]]}}}